Danaher Corporation $DHR Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Danaher Corporation (NYSE:DHR) by 3.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,861,336 shares of the conglomerate’s stock after buying an additional 68,792 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.26% of Danaher worth $412,379,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in DHR. Prime Capital Investment Advisors LLC increased its stake in shares of Danaher by 0.5% in the third quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock valued at $2,039,000 after buying an additional 45 shares in the last quarter. Essential Investment Partners LLC grew its holdings in Danaher by 34.6% during the 3rd quarter. Essential Investment Partners LLC now owns 175 shares of the conglomerate’s stock worth $39,000 after acquiring an additional 45 shares during the period. Veery Capital LLC raised its position in shares of Danaher by 3.1% during the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after acquiring an additional 48 shares during the last quarter. Studio Investment Management LLC raised its position in shares of Danaher by 3.3% during the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after acquiring an additional 51 shares during the last quarter. Finally, Meridian Financial Partners LLC lifted its stake in shares of Danaher by 1.2% in the 3rd quarter. Meridian Financial Partners LLC now owns 4,636 shares of the conglomerate’s stock valued at $1,073,000 after purchasing an additional 56 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Transactions at Danaher

In other Danaher news, CAO Christopher Bouda sold 7,598 shares of the stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total value of $1,782,186.88. Following the completion of the sale, the chief accounting officer directly owned 9,107 shares in the company, valued at $2,136,137.92. This represents a 45.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.80% of the company’s stock.

Danaher Trading Down 2.0%

Shares of NYSE DHR opened at $232.22 on Friday. The company’s fifty day moving average is $218.92 and its 200-day moving average is $201.77. The stock has a market cap of $163.37 billion, a price-to-earnings ratio of 38.01, a P/E/G ratio of 2.92 and a beta of 0.76. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The company had revenue of $6.55 billion during the quarter, compared to analyst estimates of $6.56 billion. During the same quarter in the previous year, the business earned $1.89 EPS. The firm’s revenue was up 8.3% on a year-over-year basis. Equities research analysts predict that Danaher Corporation will post 8.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were issued a dividend of $0.40 per share. The ex-dividend date was Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s payout ratio is currently 26.19%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several recent research reports. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Monday, October 26th. TD Cowen upped their price objective on Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a report on Thursday, October 22nd. JPMorgan Chase & Co. upped their price objective on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, October 22nd. Robert W. Baird increased their target price on Danaher from $246.00 to $254.00 and gave the company an “outperform” rating in a research note on Thursday, October 22nd. Finally, Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $242.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.